VLX1570 is primarily investigated for its potential in cancer therapy, particularly in targeting multiple myeloma and other hematologic malignancies. It functions as a selective inhibitor of the proteasome-associated deubiquitinase USP14, which plays a crucial role in protein degradation and cellular homeostasis. By inhibiting USP14, VLX1570 disrupts the protein degradation process, leading to the accumulation of misfolded or damaged proteins within cancer cells. This induces cellular stress and ultimately promotes apoptosis, making it a promising candidate for treating cancers that are resistant to conventional therapies. Its application is currently in the research and preclinical stages, with studies focusing on its efficacy, safety, and potential combination with other anticancer agents.